0

Close
 
Upcoming Allied Market Research
2023
Companion Diagnostics For Oncology Market

Companion Diagnostics for Oncology Market

Size, Share, Competitive Landscape and Trend Analysis Report by Product (Product, Service), by Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS, Immunohistochemistry (IHC), In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH), Other Technologies), by Disease (Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Leukemia, Melanoma, , Prostate Cancer, Others) and by End User (Hospitals, Pathology/Diagnostic Laboratory, Academic Medical Center): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A13864
Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

Companion diagnostics is a part of a comprehensive field of pharmacogenomics, which utilizes a person's genetic makeup to predict response to a therapeutic approach or design therapy personalized for the patient. The FDA defines CDx as a medical device, frequently an in-vitro device that provides information that is vital for safe and effective use of a biological product or corresponding drug. Oncology drugs are toxic and have a positive effect on a limited number of patients, primarily depending upon their phenotype or diseases. Companion diagnostics can be used to differentiate patients who will benefit from the drug and patients who can have an adverse effect of the drug. In oncology, CDx plays a major role in narrowing the population to offer the best treatment with the lowest risk.

COVID-19 Impact analysis

  • The oncology companion diagnostic market growth is negatively impacted during the first quarter of 2020 and WHO announced the COVID-19 as healthcare emergence. The nationwide lockdown was imposed by governments of many countries as the spread of disease accelerated. The oncology companion diagnostic market is significantly affected due to the ban on transportation and flights. The supply chain of this market has been disrupted due to sudden lockdown and stringent government guidelines and social distancing implementation.

Top Impacting Factors
The companion diagnostics market is expected to experience substantial growth due to the development of new biomarkers for various cancers, increase in demand for customized medicine with increased recognition in developing markets, rise in R&D, and high number of unmet cancer care requirements.
The shift in trend toward personalized medicine and rise in the prevalence of improved treatment procedures by properly analyzing diagnosis results propel the growth of the oncology companion diagnostics market.
In addition, stringent policies by the regulatory bodies to align the development timelines of diagnostics and drugs, result in the diagnostic companies broadening their scope of CDx.
The growth is expected to continue in the future owing to a substantial number of CDx associated oncology drugs in clinical trials. CDx plays an important role in clinical trial participant selection, in addition to serving as exclusive or inclusive testing for medicines. This is because if the patient has the biomarker target, a novel treatment candidate has a higher chance of showing a better response rate.
In addition, an increased focus on next-generation sequencing technology and diagnostics procedures plays a significant role in drug development, potentially influencing market growth.
Moreover, increase in number of diagnostic centres with the latest equipment with the help of private and public organisations, as well as rise in healthcare spending, contribute toward market demand.
However, lack of awareness and qualified specialists, as well as the expense of installing and maintaining the equipment, require large sums of money those small businesses cannot afford, thus hindering the Companion Diagnostics for Oncology market growth.

Market Trends
New product launches to flourish the market

  • In July 2020, the FDA approved the Ventana HER2 Dual ISH DNA Probe Cocktail assay as a quick novel method to detect HER2 biomarker for breast cancer and as a companion diagnostic for Herceptin therapy.
  • In August 2020 witnessed FDA approvals of Guardant360 CDx assay; an NGS test that uses circulating cell-free DNA as a CDx; and FoundationOne Liquid CDx; a pan-tumor liquid biopsy test.
  • In June 2020, ThermoFisher Scientific expanded its partnership with Agios Pharmaceuticals for the co-development of a companion diagnostic for vorasidenib; an investigational drug for low-grade glioma.  

Key Benefits of the Report

  • This study presents the analytical depiction of the Companion Diagnostics for Oncology along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the Companion Diagnostics for Oncology market share.
  • The current market is quantitatively analyzed to highlight the Companion Diagnostics for Oncology market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market. 
  • The report provides a detailed Companion Diagnostics for Oncology market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Companion Diagnostics for Oncology Report

  • Who are the leading market players active in the Companion Diagnostics for Oncology market?
  • What current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What future projections would help in taking further strategic steps?
  • What is "Companion Diagnostics for Oncology "?
  • What is "Companion Diagnostics for Oncology " Market prediction in the future?
  • Who are the leading global players in the "Companion Diagnostics for Oncology " Market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the "Companion Diagnostics for Oncology " Market report?

 Companion Diagnostics for Oncology Market Report Highlights

Aspects Details
By Product
  • Product
    • Instrument
    • Consumables
    • Software
  • Service
By Technology
  • Polymerase Chain Reaction (PCR)
  • Next-Generation Sequencing (NGS
  • Immunohistochemistry (IHC)
  • In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
  • Other Technologies
By Disease
  • Breast Cancer
  • Non-Small Cell Lung Cancer
  • Colorectal Cancer
  • Leukemia
  • Melanoma,
  • Prostate Cancer
  • Others
By End User
  • Hospitals
  • Pathology/Diagnostic Laboratory
  • Academic Medical Center
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players F. Hoffmann-La Roche Ltd., Myriad Genetics, Inc., Abbott, Invivoscribe, Inc., Agilent Technologies, Inc., QIAGEN N.V., Thermo Fisher Scientific, Inc, bioMérieux SA, ARUP Laboratories, Illumina, Inc.
 

Loading Table Of Content...


 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Purchase Options

 Inquire Before Buying

Call or Email Us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Companion Diagnostics For Oncology Market

Start reading.
This Report and over 71,295+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

Related Reports
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of the scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to provide pertinent information and save time for readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of the scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save the time of readers